The mucin MUC1 modulates the tumor immunological microenvironment through engagement of the lectin Siglec-9

Nature Immunology

Volumn 17, Issue 11, 2016, Pages 1273-1281

  Beatson, Richard ^a   Tajadura Ortega, Virginia ^a   Achkova, Daniela ^a   Picco, Gianfranco ^a   Tsourouktsoglou, Theodora Dorita ^a   Klausing, Sandra ^b   Hillier, Matthew ^a   Maher, John ^a   Noll, Thomas ^b   Crocker, Paul R ^c   Taylor Papadimitriou, Joyce ^a   Burchell, Joy M ^a  

^a GUY S HOSPITAL   (United Kingdom)

^b BIELEFELD UNIVERSITY   (Germany)

^c UNIVERSITY OF DUNDEE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CD163 ANTIGEN; CD33 ANTIGEN; CD8 ANTIGEN; INDOLEAMINE 2,3 DIOXYGENASE; MANNOSE RECEPTOR; MITOGEN ACTIVATED PROTEIN KINASE; MUCIN 1; PROGRAMMED DEATH 1 LIGAND 1; PROTEIN TYROSINE PHOSPHATASE SHP 1; PROTEIN TYROSINE PHOSPHATASE SHP 2; SIALIC ACID BINDING IMMUNOGLOBULIN LIKE LECTIN; SIALIC ACID BINDING IMMUNOGLOBULIN LIKE LECTIN 10; SIALIC ACID BINDING IMMUNOGLOBULIN LIKE LECTIN 7; SIALIC ACID BINDING IMMUNOGLOBULIN LIKE LECTIN 9; UNCLASSIFIED DRUG; BIOLOGICAL MARKER; LEUKOCYTE ANTIGEN; PROTEIN BINDING; SIGLEC9 PROTEIN, HUMAN;

ARTICLE; BINDING AFFINITY; CALCIUM TRANSPORT; CD8+ T LYMPHOCYTE; CELL DIFFERENTIATION; CELL PROLIFERATION; CONTROLLED STUDY; CYTOKINE RELEASE; DISEASE COURSE; GLYCOSYLATION; HUMAN; HUMAN CELL; MACROPHAGE; MONOCYTE; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR ASSOCIATED LEUKOCYTE; TUMOR MICROENVIRONMENT; UPREGULATION; BONE MARROW CELL; CELL LINE; CYTOLOGY; DENDRITIC CELL; GENE EXPRESSION; GENETICS; IMMUNOLOGY; METABOLISM; NEOPLASM; PATHOLOGY; PHENOTYPE;

ANTIGENS, CD; BIOMARKERS; CELL DIFFERENTIATION; CELL LINE; DENDRITIC CELLS; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; GENE EXPRESSION; GLYCOSYLATION; HUMANS; MACROPHAGES; MITOGEN-ACTIVATED PROTEIN KINASES; MUCIN-1; MYELOID CELLS; NEOPLASMS; PHENOTYPE; PROTEIN BINDING; SIALIC ACID BINDING IMMUNOGLOBULIN-LIKE LECTINS; TUMOR MICROENVIRONMENT;

EID: 84991736614     PISSN: 15292908     EISSN: 15292916     Source Type: Journal    
DOI: 10.1038/ni.3552     Document Type: Article

References (50)

1. Quail, D. F. & Joyce, J. A. Microenvironmental regulation of tumor progression and metastasis. Nat. Med. 19, 1423-1437 (2013).
2. Kitamura, T., Qian, B. Z. & Pollard, J. W. Immune cell promotion of metastasis. Nat. Rev. Immunol. 15, 73-86 (2015).
3. Pinho, S. S. & Reis, C. A. Glycosylation in cancer: mechanisms and clinical implications. Nat. Rev. Cancer 15, 540-555 (2015).
4. Burchell, J. M., Mungul, A. & Taylor-Papadimitriou, J. O-linked glycosylation in the mammary gland: changes that occur during malignancy. J. Mammary Gland Biol. Neoplasia 6, 355-364 (2001).
5. Gendler, S. J. et al. Molecular cloning and expression of human tumor-associated polymorphic epithelial mucin. J. Biol. Chem. 265, 15286-15293 (1990).
6. Burchell, J. et al. An alpha2, 3 sialyltransferase (ST3Gal I) is elevated in primary breast carcinomas. Glycobiology 9, 1307-1311 (1999).
7. Lloyd, K. O., Burchell, J., Kudryashov, V., Yin, B. W. & Taylor-Papadimitriou, J. Comparison of O-linked carbohydrate chains in MUC-1 mucin from normal breast epithelial cell lines and breast carcinoma cell lines. Demonstration of simpler and fewer glycan chains in tumor cells. J. Biol. Chem. 271, 33325-33334 (1996).
8. Beatson, R. et al. The breast cancer-associated glycorms of MUC1, MUC1-Tn and sialyl-Tn, are expressed in COSMC wild-type cells and bind the C-type lectin MGL. PLoS One 10, e0125994 (2015).
9. Mungul, A. et al. Sialylated core 1 based O-linked glycans enhance the growth rate of mammary carcinoma cells in MUC1 transgenic mice. Int. J. Oncol. 25, 937-943 (2004).
10. Picco, G. et al. Over-expression of ST3Gal-I promotes mammary tumorigenesis. Glycobiology 20, 1241-1250 (2010).
11. Macauley, M. S., Crocker, P. R. & Paulson, J. C. Siglec-mediated regulation of immune cell function in disease. Nat. Rev. Immunol. 14, 653-666 (2014).
12. Avril, T., Floyd, H., Lopez, F., Vivier, E. & Crocker, P. R. The membrane-proximal immunoreceptor tyrosine-based inhibitory motif is critical for the inhibitory signaling mediated by Siglecs-7 and-9, CD33-related Siglecs expressed on human monocytes and NK cells. J. Immunol. 173, 6841-6849 (2004).
13. Crocker, P. R., Paulson, J. C. & Varki, A. Siglecs and their roles in the immune system. Nat. Rev. Immunol. 7, 255-266 (2007).
14. Jandus, C. et al. Interactions between Siglec-7/9 receptors and ligands influence NK cell-dependent tumor immunosurveillance. J. Clin. Invest. 124, 1810-1820 (2014).
15. Läubli, H. et al. Engagement of myelomonocytic Siglecs by tumor-associated ligands modulates the innate immune response to cancer. Proc. Natl. Acad. Sci. USA 111, 14211-14216 (2014).
16. Hudak, J. E., Canham, S. M. & Bertozzi, C. R. Glycocalyx engineering reveals a Siglec-based mechanism for NK cell immunoevasion. Nat. Chem. Biol. 10, 69-75 (2014).
17. Tanida, S. et al. Binding of the sialic acid-binding lectin, Siglec-9, to the membrane mucin, MUC1, induces recruitment of-catenin and subsequent cell growth. J. Biol. Chem. 288, 31842-31852 (2013).
18. Bäckström, M. et al. Recombinant MUC1 mucin with a breast cancer-like O-glycosylation produced in large amounts in Chinese-hamster ovary cells. Biochem. J. 376, 677-686 (2003).
19. Zhang, J. Q., Nicoll, G., Jones, C. & Crocker, P. R. Siglec-9, a novel sialic acid binding member of the immunoglobulin superfamily expressed broadly on human blood leukocytes. J. Biol. Chem. 275, 22121-22126 (2000).
20. Carlin, A. F. et al. Molecular mimicry of host sialylated glycans allows a bacterial pathogen to engage neutrophil Siglec-9 and dampen the innate immune response. Blood 113, 3333-3336 (2009).
21. Dalziel, M. et al. The relative activities of the C2GnT1 and ST3Gal-I glycosyltransferases determine O-glycan structure and expression of a tumor-associated epitope on MUC1. J. Biol. Chem. 276, 11007-11015 (2001).
22. Qian, B. Z. et al. CCL2 recruits inflammatory monocytes to facilitate breast-tumour metastasis. Nature 475, 222-225 (2011).
23. Thapa, B., Koo, B. H., Kim, Y. H., Kwon, H. J. & Kim, D. S. Plasminogen activator inhibitor-1 regulates infiltration of macrophages into melanoma via phosphorylation of FAK-Tyr925. Biochem. Biophys. Res. Commun. 450, 1696-1701 (2014).
24. McMahon, G. A. et al. Plasminogen activator inhibitor-1 regulates tumor growth and angiogenesis. J. Biol. Chem. 276, 33964-33968 (2001).
25. Bauerle, K. T. et al. Nuclear factor B-dependent regulation of angiogenesis, and metastasis in an in vivo model of thyroid cancer is associated with secreted interleukin-8. J. Clin. Endocrinol. Metab. 99, E1436-E1444 (2014).
26. Chen, H. et al. Silencing of plasminogen activator inhibitor-1 suppresses colorectal cancer progression and liver metastasis. Surgery 158, 1704-1713 (2015).
27. Thompson, P. A. et al. Environmental immune disruptors, inflammation and cancer risk. Carcinogenesis 36 (Suppl. 1), S232-S253 (2015).
28. Oosterhoff, D. et al. Tumor-mediated inhibition of human dendritic cell differentiation and function is consistently counteracted by combined p38 MAPK and STAT3 inhibition. OncoImmunology 1, 649-658 (2012).
29. Bogdan, C. Nitric oxide synthase in innate and adaptive immunity: An update. Trends Immunol. 36, 161-178 (2015).
30. Murray, P. J. et al. Macrophage activation and polarization: nomenclature and experimental guidelines. Immunity 41, 14-20 (2014).
31. Rughetti, A. et al. Recombinant tumor-associated MUC1 glycoprotein impairs the differentiation and function of dendritic cells. J. Immunol. 174, 7764-7772 (2005).
32. Allavena, P. & Mantovani, A. Immunology in the clinic review series; focus on cancer: Tumour-associated macrophages: undisputed stars of the inflammatory tumour microenvironment. Clin. Exp. Immunol. 167, 195-205 (2012).
33. Forouzandeh, F., Jalili, R. B., Germain, M., Duronio, V. & Ghahary, A. Differential immunosuppressive effect of indoleamine 2, 3-dioxygenase (IDO) on primary human CD4+ and CD8+ T cells. Mol. Cell. Biochem. 309, 1-7 (2008).
34. Gianchecchi, E., Delfino, D. V. & Fierabracci, A. Recent insights into the role of the PD-1/PD-L1 pathway in immunological tolerance and autoimmunity. Autoimmun. Rev. 12, 1091-1100 (2013).
35. Sousa, S. et al. Human breast cancer cells educate macrophages toward the M2 activation status. Breast Cancer Res. 17, 101 (2015).
36. Qian, B. Z. & Pollard, J. W. Macrophage diversity enhances tumor progression and metastasis. Cell 141, 39-51 (2010).
37. Paul, S. P., Taylor, L. S., Stansbury, E. K. & McVicar, D. W. Myeloid specific human CD33 is an inhibitory receptor with differential ITIM function in recruiting the phosphatases SHP-1 and SHP-2. Blood 96, 483-490 (2000).
38. Christo, S. N., Diener, K. R. & Hayball, J. D. The functional contribution of calcium ion flux heterogeneity in T cells. Immunol. Cell Biol. 93, 694-704 (2015).
39. Dudley, D. T., Pang, L., Decker, S. J., Bridges, A. J. & Saltiel, A. R. A synthetic inhibitor of the mitogen-activated protein kinase cascade. Proc. Natl. Acad. Sci. USA 92, 7686-7689 (1995).
40. Xuan, Q. J. et al. Tumor-associated macrophages are correlated with tamoxifen resistance in the postmenopausal breast cancer patients. Pathol. Oncol. Res. 20, 619-624 (2014).
41. Noy, R. & Pollard, J. W. Tumor-associated macrophages: from mechanisms to therapy. Immunity 41, 49-61 (2014).
42. Garon, E. B. et al. Pembrolizumab for the treatment of non-small-cell lung cancer. N. Engl. J. Med. 372, 2018-2028 (2015).
43. Casey, S. C. et al. MYC regulates the antitumor immune response through CD47 and PD-L1. Science 352, 227-231 (2016).
44. Pardoll, D. M. The blockade of immune checkpoints in cancer immunotherapy. Nat. Rev. Cancer 12, 252-264 (2012).
45. Belisle, J. A. et al. Identification of Siglec-9 as the receptor for MUC16 on human NK cells, B cells, and monocytes. Mol. Cancer 9, 118 (2010).
46. Ohta, M. et al. Immunomodulation of monocyte-derived dendritic cells through ligation of tumor-produced mucins to Siglec-9. Biochem. Biophys. Res. Commun. 402, 663-669 (2010).
47. Correa, I. et al. Responses of human T cells to peptides flanking the tandem repeat and overlapping the signal sequence of MUC1. Int. J. Cancer 115, 760-768 (2005).
48. Priatel, J. J. et al. The ST3Gal-I sialyltransferase controls CD8+ T lymphocyte homeostasis by modulating O-glycan biosynthesis. Immunity 12, 273-283 (2000).
49. Julien, S. et al. Sialyl-Lewis(x) on P-selectin glycoprotein ligand-1 is regulated during differentiation and maturation of dendritic cells: A mechanism involving the glycosyltransferases C2GnT1 and ST3Gal I. J. Immunol. 179, 5701-5710 (2007).
50. Sproviero, D., Julien, S., Burford, B., Taylor-Papadimitriou, J. & Burchell, J. M. Cyclooxygenase-2 enzyme induces the expression of the-2, 3-sialyltransferase-3 (ST3Gal-I) in breast cancer. J. Biol. Chem. 287, 44490-44497 (2012).